CD8A and melanoma: FMT from immunotherapy‐responsive patients enhances anti‐tumour immunity in non‐responders by modulating gut microbiota, activating STING, and boosting CD8+ T‐cell infiltration, improving PD‐1 inhibitor effectiveness in melanoma